ArticleScientific reports2024

Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer.

Yifan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.